Fintel reports that on May 16, 2023, Oppenheimer reiterated coverage of POINT Biopharma Global (NASDAQ:PNT) with a Outperform recommendation.
Oppenheimer Reiterates POINT Biopharma Global (PNT) Outperform Recommendation
By 
Add A Comment